Century Therapeutics Stock News

Century Therapeutics, Inc. (NASDAQ:IPSC) shot up 5.6% on Wednesday . The company traded as high as $17.33 and last traded at $17.33. 400 shares were traded during mid-day trading, a decline of 100% from the average session volume of 174,570 shares. The stock had previously closed at $16.41. A number of brokerages have weighed in []

- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 -

Century Therapeutics, Inc. (NASDAQ:IPSC)s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $14.34 and last traded at $14.40, with a volume of 460 shares trading hands. The stock had previously closed at $15.23. Several equities analysts recently commented on the company. SVB Leerink dropped their []

Century Therapeutics (NASDAQ:IPSC) lock-up period will end on Wednesday, December 15th. Century Therapeutics had issued 10,550,000 shares in its public offering on June 18th. The total size of the offering was $211,000,000 based on an initial share price of $20.00. After the end of the companys lock-up period, company insiders and major shareholders will be []

Morgan Stanley purchased a new position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 336,223 shares of the companys stock, valued at approximately $9,865,000. Morgan Stanley owned about 0.61% of Century Therapeutics [] The post Morgan Stanley Invests $9.87 Million in Century Therapeutics, Inc. (NASDAQ:IPSC) appeared first on ETF Daily News .

Vanguard Group Inc. purchased a new stake in Century Therapeutics, Inc. (NASDAQ:IPSC) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 30,000 shares of the companys stock, valued at approximately $880,000. A number of other institutional investors also recently modified their holdings of the stock. FMR LLC purchased a new position in Century []

Century Therapeutics (NASDAQ:IPSC) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Valuation and Earnings This table compares Century Therapeutics and Mesoblasts gross revenue, earnings per share (EPS) []

Millennium Management LLC purchased a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 181,164 shares of the companys stock, valued at approximately $5,315,000. Millennium Management LLC owned approximately 0.33% of Century Therapeutics as of its most recent filing []

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participated in a fireside chat in advance of the Piper Sandler 33 rd Annual Virtual Healthcare Conference, being held November 30- December 2, 2021.

Century Therapeutics, Inc. (NASDAQ:IPSC) Research analysts at Piper Sandler dropped their FY2021 earnings per share (EPS) estimates for shares of Century Therapeutics in a research note issued to investors on Wednesday, November 10th. Piper Sandler analyst E. Tenthoff now expects that the company will post earnings of ($5.29) per share for the year, down []

Marshall Wace North America L.P. purchased a new position in Century Therapeutics, Inc. (NASDAQ:IPSC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 247,251 shares of the companys stock, valued at approximately $7,254,000. A number of other hedge funds have also []

Century Therapeutics, Inc. (NASDAQ:IPSC) Stock analysts at Piper Sandler lowered their FY2021 earnings per share estimates for Century Therapeutics in a research note issued to investors on Wednesday, November 10th. Piper Sandler analyst E. Tenthoff now expects that the company will earn ($5.29) per share for the year, down from their prior forecast of []

Collaboration enables Century to explore Outpace's protein solutions for cell therapy to enhance functionality of iPSC platform

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in imm

Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $2